19381-40-9

Basic information

• Product Name: 2-bromo-1-[3-(phenylmethoxy)phenyl]ethan-1-one
• Synonyms: 2-bromo-1-[3-(phenylmethoxy)phenyl]ethan-1-one;2-Bromo-1-[3-(phenylmethoxy)phenyl]ethanone;Einecs 243-009-7;1-[3-(benzyloxy)phenyl]-2-broMoethan-1-one;1-(3-(benzyloxy)phenyl)-2-broMoethanone;Ethanone, 2-broMo-1-[3-(phenylMethoxy)phenyl]-;1-(3-(Benzyloxy);-2-bromoethanone
• CAS NO: 19381-40-9
• Molecular Formula: C₁₅H₁₃BrO₂
• Molecular Weight: 305.16652
• EINECS: 243-009-7
• Mol File: 19381-40-9.mol

Chemical Properties

• Boiling Point: 395.5 °C at 760 mmHg
• Flash Point: 193 °C
• Appearance: /
• Density: 1.394 g/cm³
• Vapor Pressure: 1.83E-06mmHg at 25°C
• Refractive Index: 1.603
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 2-bromo-1-[3-(phenylmethoxy)phenyl]ethan-1-one(CAS DataBase Reference)
• NIST Chemistry Reference: 2-bromo-1-[3-(phenylmethoxy)phenyl]ethan-1-one(19381-40-9)
• EPA Substance Registry System: 2-bromo-1-[3-(phenylmethoxy)phenyl]ethan-1-one(19381-40-9)

Safety Data

• Hazardous Substances Data: 19381-40-9(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
2-bromo-1-[3-(phenylmethoxy)phenyl]ethan-1-one is used as a synthetic intermediate for the preparation of a wide range of organic compounds. Its versatile structure allows for various chemical reactions, facilitating the synthesis of complex organic molecules.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 2-bromo-1-[3-(phenylmethoxy)phenyl]ethan-1-one is employed as a building block in the development of new drugs and pharmaceuticals. Its unique structure and chemical properties make it a promising candidate for the synthesis of bioactive molecules with potential therapeutic applications.
Used in Drug Development:
2-bromo-1-[3-(phenylmethoxy)phenyl]ethan-1-one is utilized in drug development as a key component in the synthesis of novel pharmaceutical agents. Its chemical versatility and structural features enable the design and synthesis of innovative drug candidates with improved efficacy and selectivity.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 2-bromo-1-[3-(phenylmethoxy)phenyl]ethan-1-one is applied as a structural element in the design of new chemical entities with potential therapeutic benefits. Its unique features contribute to the discovery of novel bioactive compounds with specific pharmacological properties.
Overall, 2-bromo-1-[3-(phenylmethoxy)phenyl]ethan-1-one is a valuable chemical compound with diverse applications in organic synthesis, pharmaceutical research, drug development, and medicinal chemistry. Its unique structure and chemical properties make it an essential building block for the creation of innovative organic compounds and pharmaceutical agents.

InChI:InChI=1/C15H13BrO2/c16-10-15(17)13-7-4-8-14(9-13)18-11-12-5-2-1-3-6-12/h1-9H,10-11H2

Upstream product

• 34068-01-4 1-[3-(phenylmethoxy)phenyl]ethan-1-one 
• 100-44-7 benzyl chloride 
• 100-39-0 benzyl bromide 
• 605-65-2 5-(dimethylamino)naphth-1-ylsulfonyl chloride 
• 121-71-1 3-Hydroxyacetophenone 

Downstream Products

• 109741-79-9 1-(3-benzyloxyphenacyl)-3-ethylpyridinium bromide 
• 154621-69-9 (E,2R)-N-Benzyl-5-<2'-<3''-(benzyloxy)phenyl>-2'-oxoethylidene>proline tert-butyl ester 
• 115851-98-4 1-[2-(3-Benzyloxy-phenyl)-2-oxo-ethyl]-3,5,7-triaza-1-azonia-tricyclo[3.3.1.1^3,7]decane; bromide 
• 884331-11-7 methanesulfonic acid 3-(2-{tert-butoxycarbonyl-[2-hydroxy-2-(3-hydroxy-phenyl)-ethyl]-amino}-propyl)-1H-indol-7-yl ester 
• 884331-33-3 benzenesulfonic acid 3-(2-{tert-butoxycarbonyl-[2-(7-methanesulfonyloxy-1H-indol-3-yl)-1-methyl-ethyl]-amino}-1-hydroxy-ethyl)-phenyl ester 
• 1027488-63-6 (2R,5R)-5-<2'-(3''-Hydroxyphenyl)ethyl>proline tert-butyl ester 
• 56443-16-4 N-<2-<<2-hydroxy-2-(3-hydroxyphenyl)ethyl>amino>ethyl>-2-methylpropanamide 
• 3571-71-9 m-hydroxy-α-[(isopropylamino)methyl]benzyl alcohol 

Relevant articles and documents

UREA COMPOUNDS AND THEIR USE AS FAAH ENZYME INHIBITORS

A compound having Formula (I): wherein: R1 is selected from hydrogen, halogen, hydroxyl and C1-4 alkoxy; R2 is selected from hydrogen, halogen, hydroxyl and C1-4 alkoxy; R3 is C1-4 alkyl; R4 is aryl which is substituted with a group selected from OSO2NH2, NHCONH2, NHSO2NH2, NHSO2C1-4 alkyl and CONH2; and n is 0 or 1; or a pharmaceutically acceptable salt thereof; provided that the compound is not N-(1-benzylpiperidin-4-yl)-N-methyl-4-(4-(sulfamoylamino)phenyl)-1H-imidazole-1-carboxamide or N-(1-benzylpiperidin-4-yl)-N-methyl-4-(3-(methylsulfonamido)phenyl)-1H-imidazole-1-carboxamide. The compound may be used as an inhibitor of fatty acid amide hydrolase.

(THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS

The present invention relates to (thio)morpholine derivatives of the formula (I), wherein R1 is selected from cyano, (2-4C)alkynyl, (1-4C)alkyl, (3-6C)cycloalkyl, (4-6C)cycloalkenyl, (6-8C)bicycloalkyl, (8-10C)bicyclic group, each optionally substituted with (1-4C)alkyl, phenyl, biphenyl, naphthyl, each optionally substituted with one or more substituents independently selected from halogen, (1-4C)alkyloptionally substituted with one or more fluoro atoms, (2-4C)alkynyl, (1-4C)alkoxy optionally substituted with one or more fluoro atoms,amino, di(1-4C)alkylamino, -SO2-(1-4C)alkyl, -CO-(1-4C)alkyl, -CO-O-(1-4C)alkyl, -NH-CO-(1-4C)alkyl and (3-6C)cycloalkyl, phenyl substituted with phenoxy, benzyl, benzyloxy, phenylethyl or monocyclic heterocycle, each optionally substituted with (1-4C)alkyl, monocyclic heterocycle optionally substituted with halogen, (1-4C)alkyl or with phenyl optionally substituted with (1-4C)alkyl, and bicyclic heterocycle optionally substituted with (1-4C)alkyl; A is selected from -CO-O-, -O-CO-, -NH-CO-, -CO-NH, -C=C-, -CCH3-O- and the linking group –Y-(CH2)n-X- wherein Y is attached to R1 and selected from a bond, -O-, -S-, -SO-, -SO2-, -CH2-O-, -CO-, -O-CO-, -CO-O-, -CO-NH-, -NH-CO-, -C=C-and -C≡C-; n is an integer from 1 to 10; and X is attached to the phenylene / pyridyl group and selected from a bond, -O-, -S-, -SO-, -SO2 -, -NH, -CO-, -C=C-and -C≡C-; ring structure B optionally contains one nitrogen atom; R2 is H, (1-4C)alkyl optionally substituted with one or more fluoro atoms, (1-4C)alkoxy optionally substituted with one or more fluoro atoms, or halogen; and R3 is (1-4C)alkylene-R5 wherein the alkylene group may be substituted with (CH2)2 to form a cyclopropyl moiety or one or two halogen atoms, or R3 is is (3-6C)cycloalkylene-R5 or -CO-CH2-R5, wherein R5 is -OH, -PO3H2, -OPO3H2, -COOH, -COO(1-4C)alkyl or tetrazol-5-yl; R4 is H or (1-4C)alkyl; R6 is one or more substituents independently selected from H, (1-4C)alkyl or oxo; W is -O-, -S-, -SO- or -SO2-; or a pharmaceutically acceptable salt, a solvate or hydrate thereof; with the proviso that the derivative of formula (I) is not 2-(4-ethylphenyl)-4-morpholinoethanol or 4-[4-(2-hydroxyethyl)-2-morpholinyl]benzeneacetonitrile or a pharmaceutically acceptable salt, a solvate or hydrate thereof. The compounds of the invention have affinity to S1P receptors and may be used in the treatment, alleviation or prevention of S1P receptor mediated diseases and conditions.

A concise synthesis of a novel insulin-like growth factor i receptor (IGF-IR) inhibitor

An efficient synthesis of a potent insulin-like growth factor I receptor (IGF-IR) inhibitor AEW541 (1) is described. The key step in the synthesis is the cis-selective reductive animation of cyclobutanone, which sets up the desired 1,3-stereochemistry of the cyclobutane ring. The amino group thus generated is used as a handle to build the pyrrolopyrimidine ring. The final step resulting in 1 is accomplished by alkylation of in situ generated mesylate with azetidine.

Tryptamine-based human β3-adrenergic receptor agonists. Part 3: Improved oral bioavailability via modification of the sulfonamide moiety

The continued SAR investigation of tryptamine-based human β3-adrenergic receptor (AR) agonists is reported. Prior efforts resulted in the identification of 2 as a potent β3-AR agonist. Further modification of the left side arylsulfonamide portion in 2 provided compounds with good cell permeability, which have potent agonistic activity for β3-AR. Cinnamylamine analog 16i exhibited an excellent agonistic profile in vitro and good oral bioavailability in rats.

Efficient asymmetric hydrogenation of α-amino ketone derivatives. A highly enantioselective synthesis of phenylephrine, levamisole, carnitine and propranolol

The complexes of pyrrolidine bisphosphine ligands (CPMs) with rhodium (I) were found to be efficient catalysts for asymmetric hydrogenation of α-amino ketone hydrochloride derivatives. Utilizing this methodology, we have developed efficient asymmetric syntheses of the optically active β-amino alcohols, phenylephrine, levamisole, carnitine and propranolol.

Conformationally Constrained Analogues of Anatoxin. Chirospecific Synthesis of s-Trans Carbonyl Ring-Fused Analogues

Anatoxin is the most potent agonist known for the nicotinic acetylcholine receptor (nAChR).Although it possesses a semirigid structure, it can adopt four distinctly different conformations.Further conformationally constrained analogues of anatoxin should help to refine and discriminate among the current models for activation of this receptor.This report describes three s-trans ring-fused analogues which have been synthesized starting from D-glutamic acid and 3-hydroxyacetophenone.All of them have in common a 3-oxo-13-azatricyclo2,7>tridecane structure.They represent the first fully constrained analogues of anatoxin and are designed to serve as probes of the bioactive conformation of anatoxin at the acetylcholine nicotinic receptor site.

Substituted 1-[3-(heteroarylmethoxy)phenyl]alkanols and related compounds in the treatment of asthma

Substituted 1-[3-(heteroarylmethoxy)phenyl]-alkanols and related compounds which, by inhibiting 5-lipoxygenase enzyme and/or blocking leukotriene receptors, are useful in the prevention or treatment of asthma, arthritis, psoriasis, ulcers, myocardial infarction, stroke and related disease states in mammals; pharmaceutical compositions thereof; and a method of treatment therewith.

Oxygen Isosteric Derivatives of 3-(3-Hydroxyphenyl)-N-n-propylpiperidine

Some substituted 3-phenylmorpholines (10a-e,j,k) and 3-thienylmorpholines (10f,g), isosteres of 3-(3-hydroxyphenyl)-N-n-propylpiperidine (3-PPP), were prepared and submitted to binding assays on D-2 dopaminergic and 5-HT1 and 5-HT2 serotonergic receptors, in comparison with 3-PPP and its analogue 3a,b.The results show the loss of D-2 affinity for all morpholines, while a certain activity was still observable for piperidine derivatives.Regarding the serotonergic affinity, only chloro and methoxy derivatives (10a-d) were moderately active on the 5-HT1A receptor, either when the substituent was in the C-2 or C-3 position, whereas no tested compounds showed affinity toward the 5-HT2 receptor.